Celliaz is a KAIST faculty-founded biotech company developing a next-generation, broad-spectrum therapy for degenerative retinal diseases, aimed at fundamentally overcoming the limitations of existing treatment options and addressing major unmet clinical needs.
Unlike conventional gene therapies that target specific genetic mutations, Celliaz’s candidate therapy features a first-in-class mechanism of action that regenerates damaged photoreceptors regardless of mutation type. This innovation positions the company to serve more than 80% of patients currently underserved in the approximately KRW 20 trillion global retinal disease market, establishing a highly differentiated and scalable market opportunity.
